Bloomage Biotech(SH:688363) Xin Lang Cai Jing·2025-11-26 06:21Core Viewpoint - Huaxi Biological experienced a decline in stock price, with a year-to-date drop of 4.52% and a significant decrease in revenue and net profit for the first nine months of 2025 compared to the previous year [1][2]. Company Overview - Huaxi Biological Technology Co., Ltd. was established on January 3, 2000, and went public on November 6, 2019. The company is located in Jinan, Shandong Province, and focuses on microbial fermentation and cross-linking technology platforms to develop bioactive materials for health [1]. - The company has a full industry chain business model that includes raw materials, medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing companies, medical institutions, and end-users [1]. Financial Performance - For the period from January to September 2025, Huaxi Biological reported operating revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [2]. - The company has distributed a total of 1.138 billion yuan in dividends since its A-share listing, with 528 million yuan distributed over the past three years [3]. Shareholder Information - As of November 20, 2025, Huaxi Biological had 30,100 shareholders, a decrease of 0.62% from the previous period, with an average of 16,014 circulating shares per shareholder, which increased by 0.62% [2]. - Major shareholders include various ETFs, with significant reductions in holdings noted for several funds, indicating a potential shift in institutional investment [3].